Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samu Save Sepsis
NCT02473263Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2016
- Primary completion
- Feb 2019
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of ceftriaxone, piperacillin + tazobactam, norepinephrine, hydrocortisone in sepsis, septic shock, sponsored by Assistance publique - Hôpitaux de Paris. Started May 2016; status: completed.
02
Drugs
ceftriaxonepiperacillin + tazobactamnorepinephrinehydrocortisone
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT02473263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02473263.